Pomerantz Law Firm Notifies Hims & Hers Investors of Class Action Lawsuit Details

Investor Alert: Pomerantz Law Firm Announces Class Action Against Hims & Hers Health, Inc.

Pomerantz LLP, a leading law firm renowned for its litigation in corporate and securities matters, has informed shareholders of Hims & Hers Health, Inc. about a class action lawsuit that has been initiated against the company. This legal action centers on allegations of securities fraud which could significantly impact investors who have suffered losses during the class period.

Background of Hims & Hers

Hims & Hers Health, Inc., identified on the NYSE with the ticker symbol HIMS, has rapidly made its mark in the health sector by offering telehealth services and various wellness products. However, recent developments have raised concerns about its business practices and the integrity of its operations.

Key Allegations

The class action highlights potential misconduct involving Hims & Hers and certain of its executives. Investors are being encouraged to contact Danielle Peyton at Pomerantz LLP for further information, especially if they have made investments in Hims & Hers securities. In particular, those who purchased shares during the relevant time frame may wish to serve as lead plaintiffs in the case.

One significant event that precipitated this lawsuit was the company's partnership announcement with Novo Nordisk on April 29, 2025. This collaboration was initially perceived positively, promising a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform. Yet, only a few months later, on June 23, Novo Nordisk issued a press release terminating the partnership.

This decision stemmed from accusations that Hims & Hers was promoting and selling questionable versions of Wegovy® that could jeopardize patient safety. Letters from Novo Nordisk characterized Hims & Hers as violating legal standards with its sales practices, indicating that the active pharmaceutical ingredients in their formulations might be sourced from unapproved and potentially dangerous suppliers abroad.

Impact on Stock Prices

The termination of the partnership and the surrounding scandal had an immediate adverse effect on Hims & Hers' stock, plummeting by over 34% on June 23, 2025. This decline in share price raises serious concerns about the company's viability and the financial losses experienced by current shareholders.

How Investors Can Respond

For shareholders who wish to take action, the deadline to join the class action and potentially serve as lead plaintiff is August 25, 2025. Interested parties should gather their stock purchase information and reach out directly to Pomerantz LLP to discuss their options. Detailed instructions and copies of the official complaint can be obtained through the firm’s website at www.pomerantzlaw.com.

Conclusion

Investors in Hims & Hers are facing a turbulent time as they navigate the complexities of this lawsuit. The involvement of a firm like Pomerantz, which boasts an extensive history in advocating for victims of securities fraud, highlights the seriousness of the claims being made. For those affected, staying informed and seeking legal guidance will be crucial in these uncertain times.